Adam Kibel, MD
Adam S. Kibel, MD is Chair of Urology at Brigham and Women’s Hospital in Boston, Massachusetts. In addition, he is the DiNovi Family Chair at BWH, the Elliot Carr Cutler Professor of Surgery at Harvard University School of Medicine, Chairman of the Harvard Program in Urology Residency Program (Longwood) and Co-Leader of the Prostate Cancer Program for Dana Farber/Harvard Cancer Center. Dr Kibel received his undergraduate and medical degrees from Cornell University, completed his urology residency at the Harvard Urology Program, and his fellowship at the Brady Urologic Institute at Johns Hopkins in Baltimore, Maryland.
Dr. Kibel’s practice focused on minimally invasive treatments for urologic cancers. With over 400 peer reviewed publications, Dr Kibel’s research focuses on the identification of molecular markers of urologic tumors, integration of systemic agents earlier in the disease process and improved imaging of patients with urologic malignancies. His research has been supported by the National Cancer Institute, Prostate Cancer Foundation, American Cancer Society, American College of Surgeons, and the American Foundation for Urologic Disease.
Financial relationships
-
Attribution:SelfType of financial relationship:Consultant or Advisor (Oncology)Ineligible company:AstraZenecaDate added:Date updated:04/10/2024
-
Attribution:SelfType of financial relationship:Consultant or Advisor (Oncology)Ineligible company:BayerDate added:Date updated:04/10/2024
-
Attribution:SelfType of financial relationship:Consultant or Advisor (Oncology)Ineligible company:General ElectricDate added:Date updated:04/10/2024
-
Attribution:SelfType of financial relationship:Other (Oncology)Ineligible company:advantageneDate added:Date updated:04/10/2024
-
Attribution:SelfType of financial relationship:Consultant or Advisor (Specialty Not Specified)Ineligible company:MerckDate added:Date updated:04/10/2024
-
Attribution:SelfType of financial relationship:Consultant or Advisor (Specialty Not Specified)Ineligible company:Insight DiagnositicsDate added:Date updated:04/10/2024
-
Attribution:SelfType of financial relationship:Other (Specialty Not Specified)Ineligible company:Bristol-Myers SquibbDate added:Date updated:04/10/2024
-
Attribution:SelfType of financial relationship:Consultant or Advisor (Specialty Not Specified)Ineligible company:JanssenDate added:Date updated:04/10/2024
-
Attribution:SelfType of financial relationship:Consultant or Advisor (Specialty Not Specified)Ineligible company:ProfoundDate added:Date updated:04/10/2024